148 related articles for article (PubMed ID: 27009881)
1. A follow-up analysis of positron emission tomography/computed tomography in detecting hidden malignancies at the time of diagnosis of membranous nephropathy.
Feng Z; Wang S; Huang Y; Liang X; Shi W; Zhang B
Oncotarget; 2016 Mar; 7(9):9645-51. PubMed ID: 27009881
[TBL] [Abstract][Full Text] [Related]
2. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
[TBL] [Abstract][Full Text] [Related]
3. Screening for occult malignancy with FDG-PET/CT in patients with unprovoked venous thromboembolism.
Alfonso A; Redondo M; Rubio T; Del Olmo B; Rodríguez-Wilhelmi P; García-Velloso MJ; Richter JA; Páramo JA; Lecumberri R
Int J Cancer; 2013 Nov; 133(9):2157-64. PubMed ID: 23616232
[TBL] [Abstract][Full Text] [Related]
4. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of
Wolpert F; Weller M; Berghoff AS; Rushing E; Füreder LM; Petyt G; Leske H; Andratschke N; Regli L; Neidert MC; Stupp R; Stahel R; Dummer R; Frauenfelder T; Roth P; Reyns N; Kaufmann PA; Preusser M; Le Rhun E
Eur J Cancer; 2018 Jun; 96():64-72. PubMed ID: 29677642
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications.
Maliha PG; Hudson M; Abikhzer G; Singerman J; Probst S
Nucl Med Commun; 2019 Apr; 40(4):377-382. PubMed ID: 30664602
[TBL] [Abstract][Full Text] [Related]
7. Value of fused positron emission tomography CT in detecting primaries in patients with primary unknown cervical lymph node metastasis.
Chen YH; Yang XM; Li SS; Wang YH; He JJ; Yang YD; Wang S; Liu JJ; Zhang XL
J Med Imaging Radiat Oncol; 2012 Feb; 56(1):66-74. PubMed ID: 22339748
[TBL] [Abstract][Full Text] [Related]
8. The value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in carcinoma of an unknown primary: diagnosis and follow-up.
Yapar Z; Kibar M; Yapar AF; Paydas S; Reyhan M; Kara O; Buyukdereli G; Aydin M; Kelle AP; Unal I; Disel U; Yavuz S; Sahin B; Erkisi M
Nucl Med Commun; 2010 Jan; 31(1):59-66. PubMed ID: 19952921
[TBL] [Abstract][Full Text] [Related]
9. Additional testing following screening strategies for occult malignancy diagnosis in patients with unprovoked venous thromboembolism.
Robin P; Le Roux PY; Le Moigne E; Planquette B; Prévot-Bitot N; Roy PM; Pastre J; Merah A; Couturaud F; Le Gal G; Salaun PY
Thromb Res; 2017 Jul; 155():6-9. PubMed ID: 28460260
[No Abstract] [Full Text] [Related]
10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
11. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
Han A; Xue J; Hu M; Zheng J; Wang X
Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
[TBL] [Abstract][Full Text] [Related]
12. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
13. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
[TBL] [Abstract][Full Text] [Related]
14. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
[TBL] [Abstract][Full Text] [Related]
15. Focal fluorine-18 fluorodeoxyglucose-avid lesions without computed tomography correlate at whole-body positron emission tomography-computed tomography in oncology patients: how often are they malignant?
Kumar R; Hawkins RA; Yeh BM; Wang ZJ
Nucl Med Commun; 2011 Sep; 32(9):802-7. PubMed ID: 21685821
[TBL] [Abstract][Full Text] [Related]
16. Prediction of survival and evaluation of diagnostic accuracy whole body 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the detection carcinoma of unknown primary origin.
Tamam MO; Mulazimoglu M; Guveli TK; Tamam C; Eker O; Ozpacaci T
Eur Rev Med Pharmacol Sci; 2012 Dec; 16(15):2120-30. PubMed ID: 23280029
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography combined with computed tomography as a screening tool for occult malignancy in patients with unprovoked venous thromboembolism: an observational study.
Chauchard M; Benali K; Papo T; Sacre K
Medicine (Baltimore); 2014 Nov; 93(21):e110. PubMed ID: 25380083
[TBL] [Abstract][Full Text] [Related]
18. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
19. 18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer.
Mertens LS; Mir MC; Scott AM; Lee ST; Fioole-Bruining A; Vegt E; Vogel WV; Manecksha R; Bolton D; Davis ID; Horenblas S; van Rhijn BW; Lawrentschuk N
Urology; 2014 Feb; 83(2):393-8. PubMed ID: 24468513
[TBL] [Abstract][Full Text] [Related]
20. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
Park JW; Jo MK; Lee HM
BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
